Replimune Group Inc

Compare

466 Followers

REPL Stock Chart & Stats

$9.73

$0.17(1.56%)

At close: Jan 08 4:00 PM EST

$9.73

$0.17(1.56%)

Day’s Range― - ―

52-Week Range$2.68 - $17.00

Previous CloseN/A

Volume95.41K

Average Volume (3M)7.17M

Market Cap

$759.48M

Enterprise ValueN/A

Total Cash (Recent Filing)$403.34M

Total Debt (Recent Filing)$76.33M

Price to Earnings (P/E)―

Beta0.62

Next Earnings

May 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding78,055,850

10 Day Avg. Volume14,541,909

30 Day Avg. Volume7,174,847

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$10.00

Price Target Upside2.77% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Increased Approval ProbabilityThe probability of approval for RP1 + Opdivo in anti-PD1 failed melanoma patients has been raised to 85% from the prior 50%.

Market ConfidenceThe analyst has upgraded the stock to 'Buy' with a price target of $12 per share, reflecting confidence in the company's potential.

Regulatory ProgressThe FDA has accepted the resubmission of the Biologics License Application for RP1 + Opdivo for review, indicating progress towards potential approval.

Bears Say

Approval Process ChallengesThere is a prolonged path to approval for RP1, as Replimune will likely have to run another trial to garner approval in the U.S.

Inadequate DataThere is inadequate data to support the statistical assumption of a six-month improvement in the primary endpoint of overall survival.

Trial Design ConcernsThe FDA did not view the IGNYTE trial as an adequate and well-controlled clinical investigation, raising concerns about its effectiveness.

Replimune Group News

Replimune upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Replimune (REPL) to Buy from Neutral with a $12 price target after the company resubmitted...

6d ago

REPL

Genelux price target raised to $20 from $10 at Maxim

Maxim raised the firm’s price target on Genelux (GNLX) to $20 from $10 and keeps a Buy rating...

12d ago

GNLX

REPL

Piper upgrades Replimune to Overweight on ‘very pleasant surprise’

Piper Sandler upgraded Replimune (REPL) to Overweight from Neutral with a price target of $13, up from $8....

13d ago

REPL

Replimune upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler analyst Allison Bratzel upgraded Replimune (REPL) to Overweight from Neutral with a price target of $13,...

13d ago

REPL

Replimune upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Replimune (REPL) to Neutral from Underweight with an $11 price target Published first on TheFly –...

13d ago

REPL

Replimune upgraded to Neutral at JPMorgan after BLA resubmission accepted

As previously reported, JPMorgan upgraded Replimune (REPL) to Neutral from Underweight with an $11 price target after the...

13d ago

REPL

Midday Fly By: AWS hit by outage, Kering sells beauty unit

The major averages were broadly higher near noon as markets opened with a cautiously optimistic tone amid strong...

13d ago

Leerink upgrades Replimune on renewed confidence in RP1

Leerink analyst Jonathan Chang upgraded Replimune (REPL) to Outperform from Market Perform with a price target of $13,...

13d ago

REPL

Replimune upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Replimune (REPL) to Outperform from Market Perform. Published first on TheFly – the ultimate source for...

13d ago

REPL

Unusually active option classes on open October 20th

Unusual total active option classes on open include: Replimune Group (REPL), General Mills (GIS), Canaan Inc (CAN), U.S....

13d ago

AUR

CAN

Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Study Overview: Replimune Group is conducting a...

6d ago

REPL

Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a Phase 2,...

6d ago

REPL

Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a pivotal Phase...

6d ago

REPL

Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a Phase 1...

6d ago

REPL

REPL FAQ

What was Replimune Group Inc’s price range in the past 12 months?

Replimune Group Inc lowest stock price was $2.68 and its highest was $17.00 in the past 12 months.

What is Replimune Group Inc’s market cap?

Replimune Group Inc’s market cap is $759.48M.

When is Replimune Group Inc’s upcoming earnings report date?

Replimune Group Inc’s upcoming earnings report date is May 14, 2026 which is in 193 days.

How were Replimune Group Inc’s earnings last quarter?

Currently, no data Available

Is Replimune Group Inc overvalued?

According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Replimune Group Inc pay dividends?

Replimune Group Inc does not currently pay dividends.

What is Replimune Group Inc’s EPS estimate?

Replimune Group Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Replimune Group Inc have?

Replimune Group Inc has 78,055,850 shares outstanding.

What happened to Replimune Group Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Replimune Group Inc?

Currently, no hedge funds are holding shares in REPL

Replimune Group Stock Smart Score

Neutral

Fundamentals

Return on Equity

-73.44%

Trailing 12-Months

Asset Growth

-12.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Replimune Group Inc

Replimune Group, Inc. (REPL) is a biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates in the healthcare sector, specifically within the biopharmaceutical industry. Replimune's core products are based on its proprietary Immulytic platform, which is designed to enhance the systemic anti-tumor immune response by using genetically engineered viruses to selectively infect and kill cancer cells while sparing normal tissue.

Replimune Group (REPL) Earnings & Revenues

Historic Earnings Reports

REPL Stock 12 Month Forecast

Average Price Target

$10.00

▲(2.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","19":"$19","5.5":"$5.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.5,10,14.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,6.830769230769231,7.761538461538462,8.692307692307693,9.623076923076923,10.553846153846155,11.484615384615385,12.415384615384616,13.346153846153847,14.276923076923078,15.207692307692309,16.13846153846154,17.06923076923077,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,6.2153846153846155,6.530769230769231,6.846153846153847,7.161538461538462,7.476923076923077,7.792307692307693,8.107692307692307,8.423076923076923,8.73846153846154,9.053846153846154,9.36923076923077,9.684615384615384,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.9,5.6000000000000005,5.300000000000001,5,4.7,4.4,4.1,3.8,3.5,3.2,2.9,2.5999999999999996,2.3,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.36,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >